Stockreport

Dare´ Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Dare Bioscience, Inc.  (DARE) 
Last dare bioscience, inc. earnings: 8/14 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.darebioscience.com/investor-relations
PDF SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Dare´ Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Tec [Read more]